A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in China

The requested reference [e375d7b6fff951315d44067ec2098953843c1076] no longer exists in our database. It has been replaced by the current reference: [457cfc1e6bc4d920a1a59ead4ce5f73cb4432476]

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
The objective of this study to assess the pharmacokinetics, safety, tolerability and immunogenicity following a single subcutaneous (SC) or intravenous (IV) dose of risankizumab in healthy Chinese participants.
Epistemonikos ID: d4c91d4fadd8800988681b55520be1805aa162af
First added on: May 10, 2024